Molecular Imaging and Therapy Research Unit (MITRU)

Producing radiopharmaceuticals for diagnosis and treatment of disease
Molecular Imaging and Therapy Research Unit (MITRU)

MITRU is home to South Australia's only cyclotron - a particle accelerator that produces radioactive isotopes for use in medical imaging, treatment and research.

Mitru

MITRU is dedicated to the research, development and manufacture of radiopharmaceuticals.

The unit is licensed by the Therapeutic Goods Administration (TGA) as a manufacturer of radiopharmaceuticals which are supplied daily to hospitals and imaging centres all over Australia.

MITRU is increasingly supplying radiopharmaceuticals for research purposes including clinical trials.

The TGA undertakes regular audits of MITRU to ensure adherence to Good Manufacturing Practice (GMP) and that all guidance provided by the TGA is being followed.

Imaging

MITRU specialises in positron emission tomography (PET) imaging tracers. These tracers bind to target cells in the body and emit radiation which is detected by a PET scanner at the imaging facility.

The scanner then combines the reading with a CT scan of the patient to show where in the body the target cells are located.

MITRU is licensed to provide [18F]FDG, [18F]NaF and [18F]PSMA-1007 to hospitals and imaging centres in Australia that hold a supply agreement with SAHMRI.

Therapy

MITRU is a specialist manufacturer of Lutetium-177 [ 177Lu] based therapies.

Once administered to the patient, these therapy agents bind to the target cell (typically cancerous cells) and emit radiation. The radiation destroys the cell that it is bound to without causing irradiating surrounding tissues.

MITRU supplies [177Lu]PSMA-617 to imaging centres registered for particular clinical trials only and can supply [177Lu]PSMA I&T to imaging centres in South Australia for eligible patients under the Special Access Scheme (SAS).

scan profile

Research and Development

MITRU has research collaborations with universities, institutions and private companies. The team continues to develop new tracers to add to its portfolio of routinely produced radiopharmaceuticals using in-house produced isotopes like Fluorine-18 [18F], Copper-64 [64Cu] and Zirconium-89 [89Zr].

The unit is actively involved in researching new radiopharmaceuticals which target different cells in the body in order to image or treat new conditions.

To inquire about professional partnerships, place an order or for more information, please get in touch